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Purpose/Objective: The microscopic uncertainty of the 
energy imparted (microdosimetric spread) at the cellular/cell 
nuclei level due to the stochastic nature of ionizing radiation 
is seldom taken into account in the parameterization of 
survival fraction data. The magnitude of the microdosimetric 
spread is expected to be higher for protons than for photons 
because of the known differences in their track structure but 
very little data has been published on the matter. The aim of 
this work is to find the possible impact that variances in the 
microdosimetric spread for a cell population with diverse 
volume sizes may have on the radiation response. Particularly 
we focus on estimating the effect on the α and β parameters 
of the linear quadratic (LQ) model used to describe 
experimentally obtained cell survival curves.  
Materials and Methods: The Monte Carlo transport code 
LIonTrack was used to simulate event-by-event proton tracks 
in liquid water for the energies 0.91, 1.4, 1.72, 3.18, 3.59, 
and 4.97 MeVu-1, as well as for a 60Co source. In-house 
analysis codes were used to calculate the magnitude of the 
microdosimetric spread σz, for each radiation source and for 
a range of spherical volume sizes typical of cell nuclei. 
Experimentally obtained survival curves intrinsically account 
for the microdosimetric spread. To determine the α and β 
values that 'exclude' such variations a convolution of the dose 
dependent distribution of specific energies f (z,D) (which is a 
normal distribution characterized with mean D and a 
standard deviation σz) with the LQ equation, exp[-(αD+βD2)] 
was performed, and then fitting α and β to survival curves 
calculated from published αexp and βexp values experimentally 
obtained from exposure of V-79 cells. The RBE10 at 10% 
survival with 60Co as the reference radiation for both the 
resulting α and β values and the αexp and βexp were calculated. 
Results: The σz decreases with dose and size of the target 
volume for all radiation sources but increases with decreasing 
proton energy. For a typical fraction dose of 2 Gy, σz for a 
diameter of 10 µm is equal to 9% and 18% for the highest and 
lowest proton energy, respectively. The σz reaches 87% and 
175%, respectively, for a diameter equal to 1 µm. In contrast, 
σz for 60Co is 1.7% and 31% for 10 and 1 µm diameter. The 
ratio of RBE10 calculated by excluding σz with respect to the 
experimentally obtained, decreases with decrease in LET and 
volume. For 0.91 MeVu-1 protons, the difference ranges from 
20% to 2% for spheres with diameters 4 and 12 µm, 
respectively. That is in contrast to 4.98 MeVu-1 protons for 
which the difference does not exceed 3% for all volumes. 
Conclusions: Our data suggests that the microdosimetric 
spread in the experimental data smears out the higher 
efficiency of the RBE if the cell culture would consist of 
equal small volumes (up to 4 µm diameter). The impact of 
the microdosimetric spread in the clinical scenario when the 
irradiated volume consists of cells with diverse diameters all 
mixed together should be analysed.  
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Purpose/Objective: This study looks to determine if there 
are differences between dose to pelvic bone marrow (PBM) 
using intensity modulated radiotherapy (IMRT) versus 
conformal radiotherapy (CRT) in anal cancer and if 
differences translate to clinical implication in terms of 
haematological toxicity in patients receiving concurrent 
chemoradiation. 
Materials and Methods: Between 2009 and 2014, 46 
consecutive anal cancer patients were identified, 25 were 
treated with CRT per UK ACT II protocol and 21 were treated 
with IMRT per UK guidelines. All patients underwent weekly 
blood counts: hemoglobin (Hb), white cell count (WCC) 
including absolute neutrophil count (ANC) and Platelets 
(plts). PBM, defined as extending from iliac crest to ischial 
tuberosities, and sub structures (iliac, lower pelvis, 
lumbosacral) were contoured. IMRT and CRT sample 
population percent volume of structures receiving 5-25Gy 
(V5-V25) were tested for statistical significance, as were 
nadir blood counts. Lyman-Kutcher-Burman NTCP modeling 
was performed using parameter estimates published by Bazan 
JG et al (n=1, m=0.09 and TD50=30Gy) and 95% CI on those 
estimates. Linear and logistic regression models were used to 
test for correlation of dose metrics and blood 
counts/hematologic toxicity grade ≥3. 
Results: PBM dose metrics were significantly higher in 
patients treated with IMRT relative to those treated with 
CRT, mean PBM V5-25 was 64-90% versus 45-60% (p<0.05) 
respectively. Differences in blood nadir between the two 
groups were not statistically significant (p>0.05) in this 
sample. In total, 5 (20%) of the conformal group patients 
experienced Grade ≥3 hematologic toxicity relative to 3 (14%) 
in the IMRT group. NTCP estimates were significantly higher 
using IMRT, mean PBM NTCP at hematologic grade ≥3 toxicity 
was 13% (3-39%) using IMRT relative to 7% (4-18%) using CRT 
(p<0.05). Univariate and multivariate logistic regression of 
dose metrics and covariates against hematologic grade ≥3 
toxicity did not show significant association. Lower pelvis BM 
V5-15 was not shown to associate with lower nadir blood 
counts in the IMRT group; however, average V15 was 99%. 
Iliac BM V25 suggested an association to lower nadir WBC (β -
0.06 (k/µL), SE 0.03, p<0.1). In both groups, Iliac and 
lumbosacral BM doses were associated with lower nadir Hb (β 
-0.05 to -0.09 (k/µL) SE 0.04, p<0.05). T3/4 stage and nodal 
status showed no association to lower nadir WBC/ANC blood 
counts in the either group but were associated with reduced 
Hb and Plts.  
Conclusions: IMRT results in increased percent volume PBM 
irradiated over the 5-25Gy dose range. NTCP modeling is 
predictive of this increase resulting in an approximate 
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doubling of risk of hematologic grade ≥3 toxicity based on 
previously published NTCP parameter estimates. NTCP 
modeling well predicted toxicity using IMRT in this sample. 
Predicted toxicity using CRT lay marginally outside 95% CI 
NTCP modeling in this sample. 
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Purpose/Objective: To facilitate a prompt recommendation 
of photon vs. proton therapy a decision support system (DSS) 
is essential. This paper presents the development and 
validation of an online, three-level (dose, normal tissue 
toxicity reduction and cost-effectiveness level) proton DSS, 
and its proposed application for patients with Head and Neck 
cancer. 
Materials and Methods: Meaningful benefits were defined for 
all three levels based on expert opinions and published 
papers. For the dose comparison layer, benefit was defined 
as a plan meeting clinical acceptable organs-at-risk 
thresholds: parotid gland <26Gy, pharyngeal constrictor 
muscle superior <50Gy, supraglottis area <50Gy. For the 
toxicity reduction layer, a clinical significant grade 2+ 
toxicity reduction was set at >10% based on a published 
toxicity prediction model for xerostomia and dysphagia at 6 
and 12 months after therapy. For the cost-effectiveness 
layer, the acceptable cost for a quality-adjusted life year 
(QALY) gained was set at 80.000€ and based on a published 
Markov model. The DSS was developed with a component 
oriented design and implementation to reuse independent in-
house resources in a systematic way and implements both the 
calculations and comparisons of photons vs. protons at the 
three levels (see figure). A Head and Neck cancer patient, 
planned with both IMRT and IMPT, was used to test the DSS. 
Results: A web-based DSS was successfully developed to 
deliver layered computation and comparison services. After 
providing clinical patient information and the photon and 
proton plans, the following comparison results were 
generated (see table): (1) On a dosimetric level, proton 
therapy generated a more desirable dose distributions; (2) On 
the toxicity estimation level, proton therapy appeared more 
capable of lowering the risk of complications for xerostomia 
or swallowing dysfunction; (3) On the cost-effectiveness 
level, proton therapy was more effective although photon 
therapy was more cost-effective. 
Conclusions: This DSS is able to quantitatively compare 
photon and proton treatment options and provide multi-level 
decision support. From the limited validation, proton therapy 
demonstrates its capacity to deliver a better dose 
distribution and lower toxicity to the normal tissue in 
comparison with photon therapy. However, given the current 
acceptable payment for a QALY gained, the lower costs of 
photon therapy appears to outweigh the benefits of proton 
therapy making photons more cost-effective for this specific 
case. 
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Purpose/Objective: The reduced concentration of oxygen in 
cells (hypoxia) results in a significantly lower cell death rate 
after exposure to ionizing radiation that can lead to 
treatment failure. This oxygen effect can be expressed by 
the oxygen enhancement ratio (OER) that was found 
experimentally to be strongly related to the quality of 
radiation and, in general, to the linear energy transfer (LET). 
Studies to quantify this effect in treatment simulations have 
been pursued [Wenzl T & Wilkens, JJ (2011) Phys Med Biol, 
56; Scifoni E, et al. (2013) Phys Med Biol, 58; Bassler N, et 
al. (2014) Acta Oncol 53]. However, systematic studies to 
evaluate the impact of hypoxia in treatments with beam of 
different ion species are still lacking. Furthermore, the 
radiobiological models used to quantify the OER in these 
studies are based on the dose averaged LET estimates and do 
not explicitly distinguish among varying ion species and 
fractionation schemes. In this work a new model to predict 
the OER taking into account the specificity of the different 
ions, tissues and fractionation schemes was implemented to 
quantify the clinical outcomes of treatments with beams of 
different ion species via an intercomparison of treatment 
plans for a set of clinical cases. 
Materials and Methods: A novel model, based on the 
microdosimetric effect model [Hawkins RB (2003) Rad Res, 
160], to predict the OER was implemented. The model was 
benchmarked with in-vitro data, V79 and HSG cells in aerobic 
and hypoxic conditions, irradiated with different ions 
[Furusawa Y, et al. (2000) Rad Res, 154]. The benchmarked 
model was then included in the simulation of treatment for a 
set of 12 clinical cases (head and neck and prostate cancer) 
using p, Li, He, C and O ion beams. The plans were evaluated 
using a treatment planning system (TPS) that is able to 
evaluate the LET spectra at a voxel level for primary and 
secondary particles. The expected treatment optimality as a 
function of oxygen partial pressure, HTV size, dose per 
fraction and primary ion type, was quantified in terms of 
Tumor Control Probability (TCP) and Normal Tissue 
Complication Probability (NTCP). 
Results: The modelled OERs were found to be dependent on 
both LET and ion charge, showing also a decreasing OER for 
increasing dose per fraction with a slope that depends on the 
LET. These behaviours were found to have a good agreement 
with the experimental OER assays. The treatment simulations 
shows a substantial OER dependence by dose per fraction and 
an increase in TCP by increasing the ion charge and dose per 
fraction (e.g. up to 40% variation from p to O). However, high 
NTCP in normal tissue for high-LET radiation was also 
observed. 
